Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,766.50
Bid: 1,766.00
Ask: 1,766.50
Change: 36.50 (2.11%)
Spread: 0.50 (0.028%)
Open: 1,735.50
High: 1,766.50
Low: 1,735.00
Prev. Close: 1,730.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WRAPUP 3-West Africa Ebola outbreak could infect 20,000 people, WHO says

Thu, 28th Aug 2014 19:59

* Number of cases possibly 2-4 times higher than reported

* 12,000 local staff, 750 international experts needed

* Nigeria reports spread to main African oil hub

* Air service suspension threatens aid operation - WHO (Adds Liberian president)

By Stephanie Nebehay and Tim Cocks

GENEVA/LAGOS, Aug 28 (Reuters) - The Ebola epidemic in WestAfrica could infect over 20,000 people and spread to morecountries, the U.N. health agency said on Thursday, warning thatan international effort costing almost half a billion dollars isneeded to overcome the outbreak.

The World Health Organisation (WHO) announced a $490 millionstrategic plan to contain the epidemic over the next ninemonths, saying it was based on a projection that the virus couldspread to 10 further countries beyond the four now affected -Guinea, Liberia, Sierra Leone and Nigeria.

With the IMF warning of economic damage from the outbreak,Nigeria reported that a doctor indirectly linked to theLiberian-American who brought the disease to the country haddied of Ebola in Port Harcourt, Africa's largest energy hub.

In Britain, drugmaker GlaxoSmithKline said anexperimental Ebola vaccine is being fast-tracked into humanstudies and it plans to produce up to 10,000 doses for emergencydeployment if the results are good.

So far 3,069 cases have been reported in the outbreak butthe WHO said the actual number could already be two to fourtimes higher. "This is not a West African issue or an Africanissue. This is a global health security issue," WHO's AssistantDirector-General Dr Bruce Aylward told reporters in Geneva.

With a fatality rate of 52 percent, the death toll stood at1,552 as of Aug. 26. That is nearly as high as the total fromall recorded outbreaks since Ebola was discovered in what is nowDemocratic Republic of Congo in 1976.

The figures do not include 13 deaths from a separate Ebolaoutbreak announced at the weekend in Congo, which has beenidentified as a different strain of the virus.

Aylward said tackling the epidemic would need thousands oflocal staff and 750 international experts. "It is a bigoperation. We are talking (about) well over 12,000 peopleoperating over multiple geographies and high-risk circumstances.It is an expensive operation," he said.

The operation marks a major raising of the response by theWHO, which had been accused by some aid agencies of reacting tooslowly to the outbreak.

Medical charity Medecins sans Frontieres (MSF) welcomed theWHO plan but said the important thing was now to act upon it.

"Huge questions remain about who will implement the elementsin the plan," said MSF operations director Brice de le Vingne."None of the organisations in the most-affected countries ...currently have the right set-up to respond on the scalenecessary to make a serious impact."

EXPERIMENTAL DRUGS

Early this month, the WHO classified the Ebola outbreak asan international health emergency. Concerns that the diseasecould spread beyond West Africa have led to the use of drugsstill under development for the treatment of a handful of cases.

Two American health workers, who contracted Ebola whiletreating patients in Liberia, received an experimental therapycalled ZMapp, a cocktail of antibodies made by tiny Californiabiotech Mapp Biopharmaceutical. They recovered and were releasedfrom hospital last week.

The virus has already killed an unprecedented number ofhealth workers and is still being spread in a many places, theWHO said. About 40 percent of the cases have occurred within thepast 21 days, its statistics showed.

Previous Ebola outbreaks have mainly occurred in isolatedareas of Central Africa. However the current epidemic has spreadto three West African capitals and Lagos, Africa's biggest city.The WHO said special attention would need to be given tostopping transmission in capital cities and major ports.

"This epidemic is a challenge. Challenging to Liberia andchallenging to all of those who are friends and partners ofLiberia," President Ellen Johnson Sirleaf said on Wednesday,receiving a donation of ambulances from the Indian community.

"We can only return to our normal business ... if togetherwe beat this demon that is amongst us."

Authorities in Nigeria announced the doctor's death in PortHarcourt, the main oil industry terminal of Africa's largestcrude exporter. The doctor had treated a patient who evadedquarantine after coming into contact with Patrick Sawyer - aU.S. citizen who died in Lagos after flying in from Liberia lastmonth.

Health Ministry spokesman Dan Nwomeh wrote in his Twitterfeed that 70 people were now under surveillance in PortHarcourt, which is home to foreigners working for internationaloil companies.

A spokesman for leading operator Royal Dutch Shell said in London that the firm was "liaising with healthauthorities on the steps being taken to contain the disease".

Oil traders in Europe said insurance premiums for Nigeriancargoes had gone up slightly, but otherwise business wascontinuing as normal.

Analysts urged caution. "While major disruption to oilproduction appears unlikely, any further spread of Ebola ... islikely to cause serious operational challenges," said RoddyBarclay of the Control Risks consultancy.

According to new figures released on Thursday, Nigeria hasrecorded 17 cases, including six deaths, from Ebola, sinceSawyer collapsed upon arrival at Lagos airport in late July.

While Nigeria has yet to suffer any major economicdisruption, the International Monetary Fund said the smaller,poorer nations at the heart of the epidemic were being badlyhurt. "The Ebola outbreak is having an acute macroeconomic andsocial impact on three already fragile countries in WestAfrica," IMF spokesman Gerry Rice told reporters in Washington.

Rice said the IMF was assessing the impact and any extrafinancing needs with Guinea, Liberia and Sierra Leone.

The Lagos case contributed to the decision by a number ofairlines to halt services to Ebola-affected countries. AirFrance said on Wednesday it had suspended flights toSierra Leone on the advice of the Frenchgovernment.

Aylward said it was vital to restore commercial airlineroutes to the region to help transport aid workers and supplies,but in the meantime the WHO plan includes an "air bridge" to beoperated by the U.N.'s World Food Programme.

"We assume current airline limitations will stop within thenext couple of weeks. This is absolutely vital," he said. "Rightnow the aid effort risks being choked off."

West African health ministers meeting in Ghana on Thursdayechoed the WHO's concerns and called for the reopening ofborders and an end to flight bans. (Additional reporting by Kwasi Kpodo in Accra, Ben Hirschlerand Julia Payne in London, Anna Yukhananov in Washington andSharon Begley in New York; Writing by Joe Bavier and DanielFlynn; Editing by David Stamp)

More News
1 Nov 2023 16:52

LONDON MARKET CLOSE: Stocks prosper ahead of central bank rate calls

(Alliance News) - Stocks in London took their lead from a positive start on Wall Street to close higher as investors prepare for interest rate decisions in the UK and US.

Read more
1 Nov 2023 16:35

London close: Stocks rise ahead of US Fed policy decision

(Sharecast News) - London's stock market finished in positive territory on Wednesday, with investors keeping a keen eye on the upcoming policy announcement from the US Federal Reserve.

Read more
1 Nov 2023 08:51

TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy

(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.

Read more
1 Nov 2023 08:50

LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.

Read more
1 Nov 2023 07:40

LONDON BRIEFING: GSK raises annual guidance following Arexvy launch

(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.

Read more
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more
30 Oct 2023 07:06

GSK's Jemperli sees success in endometrial cancer trial

(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.

Read more
26 Oct 2023 09:19

TOP NEWS: GSK subsidiary ViiV receives HIV drug approval in China

(Alliance News) - GSK PLC on Thursday said its subsidiary ViiV Healthcare has received marketing authorisation in China for its cabotegravir treatment, marketed as Vocabria.

Read more
26 Oct 2023 07:02

GSK HIV injection regimen gets approval in China

(Sharecast News) - GSK announced on Thursday that its majority-owned HIV specialist subsidiary ViiV has received approval from the National Medical Products Administration (NMPA) of China for an injection regimen.

Read more
25 Oct 2023 16:01

UK earnings, trading statements calendar - next 7 days

Thursday 26 October 
Bank of Ireland Group PLCTrading Statement
Bloomsbury Publishing PLCHalf Year Results
Botswana Diamonds PLCTrading Statement
C&C Group PLCHalf Year Results
e-Therapeutics PLCHalf Year Results
Financials Acquisition CorpTrading Statement
GCP Infrastructure Investments LtdTrading Statement
HarbourVest Global Private Equity LtdHalf Year Results
Hummingbird Resources PLCTrading Statement
Hunting PLCTrading Statement
Inchcape PLCTrading Statement
International Personal Finance PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Renishaw PLCTrading Statement
Standard Chartered PLCQ3 Results
Unilever PLCTrading Statement
WPP PLCTrading Statement
Friday 27 October 
International Consolidated Airlines Group SAQ3 Results
NatWest Group PLCQ3 Results
Monday 30 October 
Airtel Africa PLCHalf Year Results
Computacenter PLCTrading Statement
Glencore PLCTrading Statement
HSBC Holdings PLCQ3 Results
Lok'n Store Group PLCFull Year Results
Pearson PLCTrading Statement
Tuesday 31 October 
BP PLCQ3 Results
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCFull Year Results
Georgia Capital PLCQ3 Results
Grit Real Estate Income Group LtdFull Year Results
RHI Magnesita NVTrading Statement
Spectris PLCQ3 Results
TP ICAP Group PLCTrading Statement
UP Global Sourcing Holdings PLCFull Year Results
Wednesday 1 November 
Asos PLCFull Year Results
Aston Martin Lagonda Global Holdings PLCQ3 Results
Beximco Pharmaceuticals LtdFull Year Results
GSK PLCQ3 Results
Next PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Weir Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
25 Oct 2023 09:35

GSK says RSV jab shows promising response in adults aged 50 to 59

(Alliance News) - GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.

Read more
25 Oct 2023 07:27

GSK hails success in US RSV vaccine trial

(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.

Read more
16 Oct 2023 08:09

TOP NEWS: GSK receives positive EU opinion on Jemperli for cancer

(Alliance News) - GSK PLC on Monday said its monoclonal antibody Jemperli is closer to becoming the first new frontline treatment option in the EU in decades for a certain form of endometrial cancer.

Read more
16 Oct 2023 07:44

LONDON BRIEFING: Hipgnosis pulls interim dividend on lower royalties

(Alliance News) - The FTSE 100 is likely to open higher on Monday, benefitting from higher oil and gas prices, while fears of escalating regional conflict in the Middle East damp risk sentiment elsewhere.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.